Philips has agreed to acquire SpectraWAVE Inc., a US-based company focused on enhanced vascular imaging and AI-supported coronary physiology assessment. The acquisition strengthens Philips’ position in image-guided therapy by adding SpectraWAVE’s HyperVue Imaging System and X1-FFR technology to its existing portfolio.
HyperVue combines advanced optical coherence tomography and near-infrared spectroscopy to provide detailed views of coronary arteries during minimally invasive heart procedures. It also uses AI to support faster image analysis and workflow efficiency. X1-FFR is an AI-enabled, angiography-based tool that calculates fractional flow reserve from a single angiogram, allowing clinicians to assess coronary physiology without additional guidewires.
These technologies will integrate with Philips’ Azurion image-guided therapy platform and complement existing solutions such as Eagle Eye Platinum IVUS and OmniWire iFR. Together, they aim to offer clinicians a broader set of imaging and physiology tools within a single workflow.
SpectraWAVE was founded in 2017 and is based in Massachusetts with a team of over 70 employees. Financial terms of the deal were not disclosed. Philips expects the acquisition to support wider adoption of intravascular imaging and physiology assessment in the treatment of coronary artery disease.
Leave a comment